Wagner, A. D. (2019). EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. Wagner , A D , Grabsch , H , Mauer , M , Marreaud , S , Caballero , C , Thuss-Patience , P , Mueller , L , Elme , A , Moehler , M H , Martens , U , Kang , Y-K , Rha , S Y , Cats , A , Tokunaga , M & Lordick , F 2019 , ' EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group ' , BMC Cancer , vol. 19 , 494 . https://doi.org/10.1186/s12885-019-5675-4.

Wagner, Anna Dorothea. "EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of Chemotherapy Alone Versus Chemotherapy Plus Trastuzumab, Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab, in the Perioperative Treatment of HER2 Positive, Gastric and Gastroesophageal Junction Adenocarcinoma On Pathologic Response Rate: A Randomized Phase II-intergroup Trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group." Wagner , A D , Grabsch , H , Mauer , M , Marreaud , S , Caballero , C , Thuss-Patience , P , Mueller , L , Elme , A , Moehler , M H , Martens , U , Kang , Y-K , Rha , S Y , Cats , A , Tokunaga , M & Lordick , F 2019 , ' EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of Chemotherapy Alone Versus Chemotherapy Plus Trastuzumab, Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab, in the Perioperative Treatment of HER2 Positive, Gastric and Gastroesophageal Junction Adenocarcinoma On Pathologic Response Rate: A Randomized Phase II-intergroup Trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group ' , BMC Cancer , Vol. 19 , 494 . Https://doi.org/10.1186/s12885-019-5675-42019.

Wagner, Anna Dorothea. "EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of Chemotherapy Alone Versus Chemotherapy Plus Trastuzumab, Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab, in the Perioperative Treatment of HER2 Positive, Gastric and Gastroesophageal Junction Adenocarcinoma On Pathologic Response Rate: A Randomized Phase II-intergroup Trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group." Wagner , A D , Grabsch , H , Mauer , M , Marreaud , S , Caballero , C , Thuss-Patience , P , Mueller , L , Elme , A , Moehler , M H , Martens , U , Kang , Y-K , Rha , S Y , Cats , A , Tokunaga , M & Lordick , F 2019 , ' EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of Chemotherapy Alone Versus Chemotherapy Plus Trastuzumab, Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab, in the Perioperative Treatment of HER2 Positive, Gastric and Gastroesophageal Junction Adenocarcinoma On Pathologic Response Rate: A Randomized Phase II-intergroup Trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group ' , BMC Cancer , Vol. 19 , 494 . Https://doi.org/10.1186/s12885-019-5675-42019.